Skip to main content

C-Rad AB (publ) (CRAD-B.ST)

Euronext Healthcare Medical - DevicesView data quality →
55.6Fair

ValueMarkers Composite Index

Top 59%#18,133 of 44,707
Overvalued

121% above intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-2.55
Low Risk
Altman
5.29
Safe
DCF Value
$1
Overvalued
ROIC
8.2%
Adequate
P/E
87.1
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

C-Rad AB (publ) (CRAD-B.ST) — VMCI valuation read

C-Rad AB (publ) (CRAD-B.ST) carries a VMCI composite of 56/100, 6 points above the Healthcare sector median of 50. Among mid-cap names, that gap places CRAD-B.ST in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The CRAD-B.ST insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads CRAD-B.ST trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 2.4x is the rate-sensitivity line to watch, the line to track on C-Rad AB (publ)'s next 10-Q.

CRAD-B.ST fell 0.6% over the trailing 7 days, with a +2.8% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in CRAD-B.ST’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.